Formycon and Biocelys Initiate FYB286 Biosimilar Project

Formycon AG, a German biosimilar developer, and Biocelys S.A., a Uruguay-based specialty pharma company, have announced a collaboration to develop a new biosimilar, FYB286. This partnership merges Formycon’s development expertise with Biocelys' advanced manufacturing capabilities. The project is financially supported by Santo Biosimilar GmbH, part of the ATHOS Group, reflecting confidence in the venture's potential.

FYB286 is set to expand Formycon’s biosimilar portfolio by targeting a niche indication with significant growth potential. The development will be conducted with a focus on cost-efficiency, aiming to meet the demands for high-quality biologic therapies in emerging markets. The project aligns with Formycon’s FYB4Growth strategy, which emphasizes strategic portfolio diversification and global market expansion.